PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.
Van't Veer, L
AffiliationDepartment of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands.
MetadataShow full item record
AbstractPhosphorylation of estrogen receptor α at serine 305 (ERαS305-P) by protein kinase A (PKA) or p21-activated kinase 1 (PAK1) has experimentally been associated with tamoxifen sensitivity. Here, we investigated the clinical application of this knowledge to predict tamoxifen resistance in ER-positive breast cancer patients. Using immunohistochemistry, a score including PAK1 and co-expression of PKA and ERαS305-P (PKA/ERαS305-P) was developed on a training set consisting of 103 patients treated with tamoxifen for metastatic disease, and validated on 231 patients randomized between adjuvant tamoxifen or no treatment. In the training set, PAK1 levels were associated with tumor progression after tamoxifen (HR 1.57, 95% CI 0.99-2.48), as was co-expression of PKA and ERαS305-P (HR 2.00, 95% CI 1.14-3.52). In the validation set, a significant tamoxifen benefit was found among the 73% patients negative for PAK1 and PKA/ERαS305-P (HR 0.54, 95% CI 0.34-0.87), while others (27%) were likely to have no benefit from tamoxifen (HR 0.88, 95% 0.42-1.82). The test for interaction showed a significant difference in recurrence-free survival between groups defined by PAK1 and PKA/ERαS305-P (P = 0.037). Elevated PAK1 and PKA/ERαS305-P appeared to influence tamoxifen sensitivity. Both PAK1 and PKA/ERαS305-P levels were associated with sensitivity to tamoxifen in breast tumors and the combination of these variables should be considered in predicting tamoxifen benefit.
CitationPKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. 2011, 125 (1):1-12 Breast Cancer Res Treat
JournalBreast Cancer Research and Treatment
- Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
- Authors: Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O
- Issue date: 2010 Mar 1
- Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
- Authors: Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G
- Issue date: 2006 May 17
- Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer.
- Authors: Holm C, Kok M, Michalides R, Fles R, Koornstra RH, Wesseling J, Hauptmann M, Neefjes J, Peterse JL, Stål O, Landberg G, Linn SC
- Issue date: 2009 Feb
- Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
- Authors: Rayala SK, Kumar R
- Issue date: 2007 Aug
- Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
- Authors: Bostner J, Ahnström Waltersson M, Fornander T, Skoog L, Nordenskjöld B, Stål O
- Issue date: 2007 Oct 25